F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have patented imidazole macrocycles acting as stimulator of interferon genes protein (STING; TMEM173) antagonists. They are reported to be useful for the treatment of cancer, autoimmune diseases, inflammatory, neurological, metabolic, cardiovascular and ocular disorders.

Research at Aurigene Oncology Ltd. has led to the identification of fused bicyclic heterocyclyl compounds acting as ubiquitin carboxyl-terminal hydrolase 1 (USP1) inhibitors and reported to be useful for the treatment of cancer.

A DE Shaw Research LLC patent reports N3-substituted uracil compounds acting as transient receptor potential cation channel subfamily A member 1 (TRPA1) antagonists. As such, they are reported to be useful for the treatment of pain, fibrosis, autoimmune disease, neurological, dermatological, cardiovascular, respiratory and gastrointestinal disorders, among others.

Wistar Institute of Anatomy & Biology has synthesized new 3C-like proteinase (3CLpro; Mpro; nsp5) (SARS-CoV-2; COVID-19 virus) inhibitors for the treatment of SARS-CoV-2 infection (COVID-19).

Frontier Medicines Corp. has patented GTPase KRAS (G12C mutant) inhibitors reported to be useful for the treatment of cancer.

Medimmune Ltd. has prepared and tested lipidated peptide analogues with improved stability acting as dual agonists of glucagon receptor (GCGR) and glucagon-like peptide 1 receptor (GLP-1R). They are reported to be useful for the treatment of obesity, nonalcoholic steatohepatitis (NASH) and type 2 diabetes.

Research at the University of Illinois has led to the identification of temozolomide prodrugs reported to be useful for the treatment of cancer.

Katholieke Universiteit Leuven and Springworks Therapeutics Inc. have jointly identified tetrahydropyridopyrimidines acting as transcriptional coactivator YAP1/transcriptional enhancer factor (TEAD) or WW domain-containing transcription regulator protein 1 (WWTR1; TAZ)/TEAD interaction inhibitors.

A Retune Pharma Inc. patent describes new insulin-like growth factor 1 receptor (IGF-1R; CD221) inhibitors reported to be useful for the treatment of cancer, thyroid-associated ophthalmopathy (Graves ophthalmopathy) and autoimmune disease.

Arvinas Operations Inc. has reported the development of diacylglycerol kinase α (DGK-α; DGKA) inhibitors reported to be useful for the treatment of cancer.